Tag: KRAS
Lupin achieves key milestones for its potential therapy to treat difficult...
Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancer...........................